SANOFI CONS HEALTHC IND L Total Liabilities

Latest as of December 2025: Rs1.63 Billion INR ≈ $17.63 Million USD

SANOFI CONS HEALTHC IND L total liabilities. Based on the latest financial reports, SANOFI CONS HEALTHC IND L (SANOFICONR) has total liabilities worth Rs1.63 Billion INR (≈ $17.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SANOFICONR asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of SANOFI CONS HEALTHC IND L (2023–2025)

Total liabilities of SANOFI CONS HEALTHC IND L from 2023 to 2025. This chart illustrates how SANOFI CONS HEALTHC IND L's total liabilities have evolved over time, based on quarterly financial data.

SANOFI CONS HEALTHC IND L Competitors by Total Liabilities

The table below lists competitors of SANOFI CONS HEALTHC IND L ranked by their total liabilities.

Company Country Total Liabilities
Beijing eGOVA
SHE:300075
China CN¥612.11 Million
Beijing Hualu Baina Film TV
SHE:300291
China CN¥1.12 Billion
CGN Nuclear Technology Development Co Ltd
SHE:000881
China CN¥4.48 Billion
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
USA $688.55 Million
Fujian Boss Software Development Co Ltd
SHE:300525
China CN¥1.29 Billion
Artis Real Estate Investment Trust
TO:AX-UN
Canada CA$1.19 Billion
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
China CN¥7.52 Billion
Netac Tech
SHE:300042
China CN¥539.58 Million

Liability Composition Analysis (2023–2025)

This chart breaks down SANOFI CONS HEALTHC IND L's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SANOFICONR asset base.

Liquidity & Leverage Metrics

SANOFI CONS HEALTHC IND L Total Liabilities Ratios Explained

SANOFI CONS HEALTHC IND L total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.85 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SANOFI CONS HEALTHC IND L's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SANOFI CONS HEALTHC IND L (2023–2025)

The table below shows the annual total liabilities of SANOFI CONS HEALTHC IND L from 2023 to 2025.

Year Total Liabilities Change
2025-12-31 Rs1.63 Billion
≈ $17.63 Million
+2.97%
2024-12-31 Rs1.58 Billion
≈ $17.12 Million
+14.88%
2023-12-31 Rs1.38 Billion
≈ $14.90 Million
--

About SANOFI CONS HEALTHC IND L

NSE:SANOFICONR India Drug Manufacturers - General
Market Cap
$851.86 Million
Rs78.77 Billion INR
Market Cap Rank
#9278 Global
#462 in India
Share Price
Rs3420.20
Change (1 day)
-0.69%
52-Week Range
Rs3207.90 - Rs5026.80
All Time High
Rs5696.00
About

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was in… Read more